Research/art/teacher profile of a person
Name and surname:
prof. MUDr. Stanislav Špánik, PhD.
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Špánik
I.2 - Name
Stanislav
I.3 - Degrees
MD prof. PhD MHA
I.4 - Year of birth
1959
I.5 - Name of the workplace
I. Oncological Clinic
I.6 - Address of the workplace
Dean´s office, MF UK, Špitálska 24, 813 72 Bratislava
I.7 - Position
special assistent
I.8 - E-mail address
stanislav.spanik@fmed.uniba.sk
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/detail/3476
I.10 - Name of the study field in which a person works at the university
clinical oncology
I.11 - ORCID iD
0000-0001-8104-6403

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.2 - Second degree of higher education
II.a - Name of the university or institution
Faculty of Medicine Charles University Prague, Faculty of Medicine Comenius University Bratislava
II.b - Year
1978 - 1984
II.c - Study field and programme
General Mediicne
II.3 - Third degree of higher education
II.a - Name of the university or institution
Faculty of Medicine Comenius University Bratislava
II.b - Year
1995
II.c - Study field and programme
Internal Medicine
II.4 - Associate professor
II.a - Name of the university or institution
School of Nursing and Public Health, University of Trnava
II.b - Year
1996
II.c - Study field and programme
Public Health
II.5 - Professor
II.a - Name of the university or institution
School of Nursing and Public Health, University of Trnava
II.b - Year
2002
II.c - Study field and programme
Public Health
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
Special assistent I. Oncological Clinic, Faculty of Medicine Comenius University Bratislava 2008 - ongoing
consultant in clinical oncology St. Elisabeht Cancer Institute 2023 - ongoing
Head of department Department of Medicine and Medical Oncology, St. Elizabeth Cancer Institute 1996 - 2023
State secretary Ministry of Health 2016 - 2020

IV. - Development of pedagogical, professional, language, digital and other skills

IV.a - Activity description, course name, other IV.b - Name of the institution IV.c - Year
1st degree Internal Medicine Board Examination Postgraduate Medical School 1987
Haematology and Blood Transfusion Board Examination Postgraduate Medical School 1991
Clinical Oncology Board Examination Postgraduate Medical School 1994
MHA St. Elisabeth University of Health and Social Work 2020

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.c - Dissertation (third degree)
2
V.4.2 - Number of defended theses
V.4.b - Diploma (second degree)
3
V.4.c - Dissertation (third degree)
2
V.5 - Overview of other courses taught in the current academic year according to study programmes

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
318
VI.1.b - Over the last six years
9
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
13
VI.1.b - Over the last six years
1
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
1550
VI.1.b - Over the last six years
306
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
1298
VI.1.b - Over the last six years
295
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
57
VI.1.b - Over the last six years
10
VI.2 - The most significant research/artistic/other outputs
1

Špánik S, Grausová S, Stopková K, Krúpová I, Trupl J, Kunová A, Kukučková E, Ilavská I,

Heľpianská L, Oravcová E, Lacka J, Koreň P, Bezáková I, Grey E, Krčméry V:

Corynebacterial Bacteremia in Cancer Patients: Analyzing Risk Factors and Outcome in 41

Monomicrobial versus Polymicrobial Bacteremic Episodes. Antimicrobial Agents and

Chemotherapy. 1997; 15 (2/3): 59-63. (IF = 3,560; Q1)





2

Špánik S, Trupl J, Krčméry V: Nosocomial catheter-associated Flavobacterium odoratum

bacteraemia in cancer patients. Journal of Medical Microbiology. 1998; 47 (2): 183. (IF

=1,961; Q2)

3

Zielinski, C, Beslija, S, Mrsic-Krmpotic, Z, Welnicka-Jaskiewicz, M, Wiltchke, C, Kahan, Z, Grgic,

M, Tzekova, V, Inbar, M, Cervek, J, Chernozemsky, I, Szanto, J, Špánik, Stanislav et al.:

Gemcitabine, epirubicin, and paclitaxelversus fluorouracil, epirubicin, and cyclophosphamide

as first-line chemotherapy in metastatic breast cancer: A central European cooperative

oncology group international, multicenter, prospective, randomized phase III trial

Journal of Clinical Oncology. 2005; 23, 7; 1401-1408. (IF = 11,810; Q1)

4

Huinink, W. W. T, Šufliarsky, J, Smit, W. M, Špánik, S, Wagnerová, M, Hirte, H. W, Kaye, S, Johri,

S, Oza, A. M: Safety and efficacy of patupilone in patients with advanced ovarian, primary

fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study

Journal of Clinical Oncology. 2009; 27 (19): 3097-3103. (IF = 17,793; Q1)

5

Čierna Z, Mego M, Novotná V, Macháleková K, Chovanec M, Světlovská D, Kaľavská K,

Rejleková K, Macák D, Špánik S, Ondruš D, Kajo K, Mardiak J, Babál P: Prognostic value of

programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.

Annals of Oncology. 2016; 27 (2): 300-305. (IF = 11,855; Q1)

.

VI.3 - The most significant research/artistic/other outputs over the last six years
1

Špánik S, Balogová S, Beržinec P, Boboková J, Durdík Š, Gočárová K, Havlík B, Chorváth M, Kajo

K, Krajcsovics K, Kunderlík M, Lakota J, Lehotská V, Mriňáková B, Novotná V, Ondruš D,

Ondrušová M, Palacka P, Slabá B, Sorkovská D, Tarbaj L, Vertáková-Krakovská B, Záhorec R,

Zuzák P:

Introduction to Clinical Oncology. - 1. vyd. - Bratislava : Univerzita Komenského v Bratislave,

2021. - 406 s.





2

Špániková B, Špánik S: Miesto a postavenie vitamínu D v liečbe sekundárnej osteoporózy u

onkologických pacientov = The role of vitamin D in the treatment of secondary osteoporosisin

cancer patients

Clinical Osteology. 2018; 23 ( 4): 169-175. Q4

3

Špánik S, Lakota J, Ondrušová M: Zhubné nádory hematopoietického a retikuloendotelového

tkaniva

In: Špeciálna onkológia. - Bratislava : Solen (SK), 2020. - S. 236-271 [5,24 AH]. - ISBN 978-80-89858-18-7

4

Chovanec M, Čierna Z, Novotná V, Macháleková K, Kaľavská K, Rejleková K, Světlovská D,

Macák D, Špánik S, Kajo K, Babál P, De Giorgi U, Mego M, Mardiak J: Systemic immuneinflammation

index in germ-cell tumours. British Journal of Cancer. 2018; 118 ( 6): 831-838. (IF = 5,416; Q1)

5

Chovanec M, Čierna Z, Novotná V, Macháleková K, Kaľavská K, Rejleková K, Světlovská D,

Macák D, Špánik S, Kajo K, Babál P, Mego M, Mardiak J::Beta-catenin is a marker of poor clinical

characteristics and suppressed immune infiltration in testicular germ cell tumors. BMC

Cancer. 2018; 18: 1-10, (IF = 2,933; Q1)

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

Zielinski C, Beslija S, Mrsic-Krmpotic Z, Welnicka-Jaskiewicz, M, Wiltchke,C, Kahan Z, Grgic

M, Tzekova V, Inbar M, Cervek J, Chernozemsky I, Szanto J, Špánik S et al.: Gemcitabine,

epirubicin, and paclitaxelversus fluorouracil, epirubicin, and cyclophosphamide as first-line

chemotherapy in metastatic breast cancer: A central European cooperative oncology group

international, multicenter, prospective, randomized phase III trial. Journal of Clinical Oncology.

2005; 23, 7; 1401-1408

Cited in: Mauri D, Polyzos N.P, Salanti G, Pavlidis N, Ioannidis J.P.A.: Journal of the National

Cancer Institute, vol. 100, 24, 2008, s. 1780-1791





2

Huinink, W. W. T, Šufliarsky, J, Smit, W. M, Špánik, S, Wagnerová, M, Hirte, H. W, Kaye, S, Johri,

S, Oza, A. M: Safety and efficacy of patupilone in patients with advanced ovarian, primary

fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study

Journal of Clinical Oncology. 2009; 27 (19): 3097-3103.

Cited in: Colombo N, Kutarska E, Dimopouls M et al. Journal of Clinical Oncology. 2012; 30(31): 3841-3847.

3

Špánik S, Trupl J, Krčméry V: Nosocomial catheter-associated Flavobacterium odoratum

bacteraemia in cancer patients. Journal of Medical Microbiology. 1998; 47 (2): 183

Cited in: Yang S, Liu Q, Shen Z, Wang H, He L: Infection and Drug Resistance, vol. 13, 2020: 1981-1993

4

4 Čierna Z, Mego M, Novotná V, Macháleková K, Chovanec M, Světlovská D, Kaľavská K,

Rejleková K, Macák D, Špánik S, Ondruš D, Kajo K, Mardiak J, Babál P: Prognostic value of

programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.

Annals of Oncology. 2016; 27 (2): 300-305

Cited in: Tsimberidou A.M, Vo H.H, Subbiah V, Janku Fet al. Oncologist, 2021; 26 (7): 558-e1098

5

5 Chovanec M, Čierna Z, Novotná V, Macháleková K, Kaľavská K, Rejleková K, Světlovská D,

Macák D, Špánik S, Kajo K, Babál P, Mego M, Mardiak J::Beta-catenin is a marker of poor clinical

characteristics and suppressed immune infiltration in testicular germ cell tumors. BMC

Cancer. 2018; 18: 1-10,

Cited in: Evmorfopoulos K, Marsitopoulos K, Karachalios R, Karathanasis A, Dimitropoulos K,

Tzortzis V, Zachos I, Vllachostergios P.J.: The Immune Landscape and Immunotherapeutic

Strategies in Platinum-RefractoryTesticular Germ Cell Tumors. In: Cancers, 2024; 16 (2): 428

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VII.a - Activity, position VII.b - Name of the institution, board VII.c - Duration
member of the scientific council St. Elisabeth University of Health and Social Work 2003 - ongoing
member of the scientific council Faculty of Medicine, Slovak Health University 2016 - 2020

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

VIII.a - Name of the institution VIII.b - Address of the institution VIII.c - Duration (indicate the duration of stay) VIII.d - Mobility scheme, employment contract, other (describe)
Department of Medicine, Memorial Sloan-Kettering Cancer Centre New York, NY, USA 1993 - 6 months
Department of Medicine, Mayo Clinic Rochester, MN, USA 1996 - 2 months

IX. - Other relevant facts

IX.a - If relevant, other activities related to higher education or research/artistic/other activities are mentioned

chairman of editorial board of the magazine Onkologia

member of the editorial board of the magazine Klinicka onkologia

member of the editorial board of the magazine MEMO - Magazine of European Medical Oncology

president of the committee of the Slovak oncological society

member of the presidium of Slovak Medical Association


Date of last update
2025-02-26